You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):環孢素A眼凝膠測試分數均比基線改善
格隆匯 03-11 20:47

格隆匯3月11日丨李氏大藥廠(00950.HK)公佈,集團聯營公司Zhaoke Ophthalmology Limited(兆科眼科)於經同行評審的國際性藥物治療期刊Clinical Therapeutics刊登其自創環孢素A眼凝膠的第二期臨牀試驗數據。有關文章公佈環孢素A眼凝膠治療中至嚴重程度乾眼症的第二期臨牀試驗數據,環孢素A眼凝膠在不同劑量及用藥頻率下展現出優異的安全性、耐受性及效能。

在十二週治療期間,環孢素A眼凝膠的全部三個實驗組別的眼乾分數及6項其他乾眼症狀指標、角膜螢光素染色法、崩裂時間和Schirmer測試分數均比基線改善,改善程度與Restasis相若。根據GlobalData Plc,於2026年,中國將有6425萬宗乾眼症確診流行病例,在八大市場(美國、法國、德國、意大利、西班牙、英國、日本及中國)中數量最多。

據悉,環孢素A為天然的環狀多肽免疫抑制劑,擔當鈣調神經磷酸酶抑制劑,抑制T淋巴細胞釋放促炎性細胞因子。兆科眼科開發的環孢素A眼凝膠為專利產品,在臨牀前研究中顯示出較乳劑配方(Restasis)具有更佳的藥代動力學特性。於第二期直接比較對照試驗中,環孢素A眼凝膠每天一次的用量展示出的療效及安全特性至少與Restasis(b.i.d.)類近。環孢素A眼凝膠目前正於中國進行第三期開發,以治療中至嚴重程度乾燥性角膜結膜炎(乾眼症)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account